Key result
Orsiro sirolimus-eluting stents show comparable 1-year mural thrombus rates between stable angina and ACS patients.
Why the study?
Imaging modality-based evidence comparing the extent of coronary arterial repair after percutaneous coronary intervention between patients with stable angina pectoris and those with acute coronary syndrome is limited.
Does the extent of coronary arterial repair after ultrathin biodegradable polymer sirolimus-eluting stent implantation differ between patients with stable angina pectoris and acute coronary syndrome?
Observational (n=92)
No
Does the extent of coronary arterial repair after ultrathin biodegradable polymer sirolimus-eluting stent implantation differ between patients with stable angina pectoris and acute coronary syndrome?
Ultrathin biodegradable polymer sirolimus-eluting stents induce similar coronary arterial repair at 1 year in patients with stable angina pectoris and acute coronary syndrome.
Supports similar repair with Orsiro stents across presentations; hypothesis-generating and should not yet change practice.
BACKGROUND: Imaging modality-based evidence is limited that compares the extent of coronary arterial repair after percutaneous coronary intervention between patients with stable angina pectoris (SAP) and those with acute coronary syndrome (ACS). METHODS: Between December 2018 and November 2021, a single-center, nonrandomized, observational study was conducted in 92 patients with SAP (n = 42) or ACS (n = 50), who were implanted with Orsiro sirolimus-eluting stent (O-SES) providing a hybrid (active and passive) coating and underwent 1-year follow-up by coronary angioscopy (CAS) after implantation. CAS assessed neointimal coverage (NIC), maximum yellow plaque (YP), and mural thrombus (MT). RESULTS: Baseline clinical characteristics were comparable between the SAP and ACS groups. The follow-up periods were comparable between the two groups (390.1 ± 69.9 vs. 390.6 ± 65.7 days, p = 0.99). The incidences of MT at 1 year after implantation were comparable between the two groups (11.4% vs. 11.1%, p = 0.92). The proportions of "Grade 1" in dominant NIC grades were highest in both groups, and the proportions of maximum YP grades and MT were comparable between the two groups. CONCLUSION: O-SES-induced coronary arterial repair at the site of stent implantation, irrespective of the types of coronary artery disease.
No takes yet. Share an insight, caveat, or question.
Ichikawa et al. (2023) conducted an observational in Stable angina pectoris or acute coronary syndrome (n=92). Orsiro sirolimus-eluting stent (O-SES) in stable angina pectoris vs. Orsiro sirolimus-eluting stent (O-SES) in acute coronary syndrome was evaluated on Incidence of mural thrombus at 1 year (p=0.92). Orsiro sirolimus-eluting stents showed comparable 1-year mural thrombus incidence between stable angina and acute coronary syndrome patients (11.4% vs 11.1%, p=0.92).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: